{"id":"NCT02518139","sponsor":"Mylan Inc.","briefTitle":"A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A Phase 3, 52-week, Randomized, Active-Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09","primaryCompletion":"2017-06","completion":"2017-06","firstPosted":"2015-08-07","resultsPosted":"2018-12-31","lastUpdate":"2022-02-24"},"enrollment":1060,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"TD-4208","otherNames":["revefenacin"]},{"type":"DRUG","name":"Tiotropium","otherNames":[]}],"arms":[{"label":"TD-4208-1","type":"EXPERIMENTAL"},{"label":"TD-4208-2","type":"EXPERIMENTAL"},{"label":"Tiotropium","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.","primaryOutcome":{"measure":"Adverse Events: Frequency and Severity","timeFrame":"Baseline to Day 365","effectByArm":[{"arm":"TD-4208-1","deltaMin":272,"sd":null},{"arm":"TD-4208-2","deltaMin":242,"sd":null},{"arm":"Tiotropium","deltaMin":275,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["38560416","32343967","31666076","31150963"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":364},"commonTop":["Chronic Obstructive Pulmonary Disease","Nasopharyngitis","Upper Respiratory Tract Infection","Cough","Dyspnoea"]}}